Jaguar Health, INC 8-K filings

Jaguar Health amends royalty payment terms with Uptown Capital and Streeterville Capital, extending payment initiation to January 1, 2027, and declares a special stock dividend of Series R Preferred Stock to common shareholders.

Jaguar Health, Inc. has exchanged a portion of its outstanding debt for shares of its common stock, reducing its principal balance by $3.4 million.

Jaguar Health, Inc. has exchanged a portion of its outstanding secured promissory note for shares of its common stock, reducing its debt balance.

Jaguar Health, Inc. has filed a Form 8-K detailing the elimination of multiple series of preferred stock and the completion of a 1-for-15 reverse stock split.

Jaguar Health, Inc. has entered into multiple agreements to exchange outstanding debt for common stock and pre-funded warrants, impacting its capital structure.

Jaguar Health, Inc. announced the effectuation of a 1-for-15 reverse stock split, effective September 17, 2026, to comply with Nasdaq listing standards.

Jaguar Health announced its second quarter 2026 financial results, reporting a 59% decrease in total revenue to $1.2 million and a widened net loss of $12.7 million.

Jaguar Health, Inc. announced the completion of its Series O Preferred Stock conversion into common stock, impacting outstanding share counts and warrant entitlements.

Jaguar Health has initiated the mandatory conversion of its Series O Convertible Preferred Stock into common shares while updating its manufacturing supply agreements.

Jaguar Health, Inc. has amended its royalty and note agreements with Uptown Capital, LLC and Streeterville Capital, LLC, adjusting payment terms and maturity dates.

Jaguar Health announces a $40 million equity line of credit and a $2 million preferred stock financing to bolster corporate purposes and strategic initiatives.

Jaguar Health shareholders approved all five proposals at the reconvened 2026 Annual Meeting, including authorizations for significant equity and preferred stock issuances.

Jaguar Health, Inc. has completed two exchange transactions with Streeterville Capital, LLC, issuing common stock in exchange for preferred stock.

Jaguar Health announced it has regained compliance with the Nasdaq Bid Price Rule, ensuring its continued listing on the Nasdaq Stock Market.

Jaguar Health issued 54,222 common shares to Streeterville Capital to retire preferred stock and adjourned its 2026 Annual Meeting.

Jaguar Health announced a significant 816% year-over-year increase in first-quarter 2026 revenue, primarily driven by licensing agreements for its Mytesi and Canalevia-CA1 products.

Jaguar Health, Inc. has exchanged a significant portion of its outstanding royalty interests for Series Q Preferred Stock, restructuring its debt obligations with Uptown Capital and Streeterville Capital.

Jaguar Health has received an extension from the Nasdaq Hearings Panel to demonstrate compliance with the minimum $1.00 bid price requirement.

Jaguar Health announced it has regained compliance with Nasdaq's minimum publicly held shares requirement following the exercise of pre-funded warrants.

Jaguar Health received a Nasdaq notification regarding non-compliance with the minimum publicly held shares requirement following a reverse stock split, risking delisting.

Jaguar Health has received an extension until May 15, 2026, to comply with Nasdaq's bid price rule and will implement a 1-for-35 reverse stock split effective April 30, 2026.

Jaguar Health, Inc. announced the approval of all five proposals at its April 20, 2026 Special Meeting of Stockholders, including an increase in authorized shares and a reverse stock split.

Jaguar Health reports regaining Nasdaq compliance with stockholders' equity exceeding $2.5 million as of April 7, 2026, following various capital infusions and debt extinguishment.

Jaguar Health reported a 2025 net loss of $53.6 million while securing a $16 million non-dilutive licensing deal to pivot toward rare-disease treatments.

Jaguar Health, Inc. received a notice from Nasdaq indicating non-compliance with listing rules due to its stock price falling below $1.00, initiating potential delisting proceedings.

Jaguar Health, Inc. filed a Certificate of Designation for its Series O Convertible Preferred Stock, detailing the terms for a special one-time dividend.

Jaguar Health, Inc. exchanged royalty interests and preferred stock for pre-funded common stock purchase warrants with Iliad Research and Trading, L.P. and Streeterville Capital, LLC.

Jaguar Health's subsidiary Napo Pharmaceuticals has licensed U.S. commercialization rights for Mytesi and Canalevia-CA1 to Future Pak, securing an $18 million upfront payment and up to $17 million in milestones.

Jaguar Health, Inc. filed an amended 8-K to correct prior errors and detail the issuance of $350,000 in unsecured promissory notes and warrants to accredited investors.

Jaguar Health, Inc. announced it secured $350,000 in short-term unsecured promissory notes with 6% interest and issued warrants to purchase 350,000 common shares to accredited investors.